Investor Presentation Full Year 2021 slide image

Investor Presentation Full Year 2021

63 Investor presentation Full year 2021 Novo NordiskⓇ In STEP 4, 41.2% of patients treated with semaglutide reached ≥20% weight loss and reported improved quality of life vs placebo Categorical weight loss Sema 2.4 mg showed a statistically significant treatment difference versus placebo in the SF-36 patient reported outcome ETD [95% CI] 2.46 [1.59 3.32] * 1.44 [0.42 2.47] * 2.23 [-0.06 4.53] 1.86 [0.733.00] * Proportion of patients SF-36 scores 100% 90.5% Sema 2.4 mg Placebo Physical functioning 80.8% 80% 60% 50.0% 40% 20% 0% ≥5% ≥10% ≥15% ≥20% Weight loss H 20.9% 9.8% 65.5% 41.2% Role-physical Bodily pain General health Vitality Social functioning Role-emotional Mental health 5.1% Physical component summary Mental component summary Favours placebo Favours semaglutide -1012 3 4 5 6 7 8 Descriptive statistics only. Based on the on-treatment data, i.e. data for people that are on-treatment at week 68 Sema: semaglutide 4.31 [1.617.02] * 2.41 [0.07 4.76] * 1.64 [0.52 2.76] * 2.93 [1.80 4.06] 1.68 [0.64 2.72] * 3.44 [2.28 4.60] * * * statistically significant; p-values other than physical functioning were not controlled for multiplicity CI: confidence interval, ETD: estimated treatment difference, Sema: semaglutide, SF-36: Short Form (36) Health Survey
View entire presentation